The Latest

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    AbbVie is paying up to $757 million in a deal to license two experimental migraine drugs from Beijing-based Brise Pharmaceuticals.

    Updated 20 hours ago
  • A colorful stock market ticker
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    This week in charts: ESMO’s winners and losers

    The latest installment in BioPharma Dive’s visualization-focused series looks at Wall Street’s response to a trio of closely watched presentations at a top meeting for cancer drugs.

  • A photo of Wall Street in New York City in 2022.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game

    Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.

  • Three people work in Empress Therapeutics' lab.
    Image attribution tooltip
    Permission granted by Empress Therapeutics
    Image attribution tooltip
    Startup launches

    Flagship blends three biotech startups to form Etcelera

    Etiome, Cellarity and Empress Therapeutics are being combined into one new AI-aided drugmaker claiming to possess the ability to better predict the way new medicines will fare in humans.

  • A man in a blue suit stands for a photo.
    Image attribution tooltip
    Permission granted by Actio Bio
    Image attribution tooltip
    Startup launches

    With Setara, the team behind Actio opens its second act

    The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that Actio was working on when Jazz Pharmaeuticals bought its lead epilepsy program.

  • A person points to the start of a successful business on a blue stock market graph.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Aspen raises a $141M IPO in pursuit of a cell therapy for Parkinson’s

    The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or even halt the neurodegenerative condition.

  • An exterior of a building.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    Labor Department finalizes sweeping PBM disclosure rule

    Starting in 2027, the controversial drug middlemen will have to share a broad swath of fee and compensation data with self-funded employer clients. Employers cheered the rule, while PBMs slammed it as government overreach.

  • U.S. Health and Human Services Secretary Robert F. Kennedy Jr. testifies during a hearing of the House Education And Workforce Committee on Capitol Hill on April 17, 2026 in Washington, DC.
    Image attribution tooltip
    Heather Diehl/Getty Images via Getty Images
    Image attribution tooltip
    Trump administration

    HHS to allow compounders to make 6 unapproved peptides

    RFK Jr. has given notice that the agency won’t take enforcement action on six peptides that controversially won a contested recommendation from outside advisers to the FDA in July.

    FDA
  • A picture of FDA commissioner Kyle Diamantas speaking at an event in Washington DC.
    Image attribution tooltip
    Win McNamee / Staff via Getty Images
    Image attribution tooltip
    Gene editing

    FDA unveils guidance for ‘plug and play’ gene therapies

    The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies benefiting different subsets of patients with the same disease.

    FDA
  • The Genmab logo is pictured on a teal wall.
    Image attribution tooltip
    Courtesy of Genmab A/S
    Image attribution tooltip

    Genmab soars to record highs after cancer drug succeeds in key trial

    The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become a new treatment standard for a form of head and neck cancer.

  • DNA double helix surrounded by malignant cancer cells and pathogens
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data

    At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.

  • Boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California.
    Image attribution tooltip
    Mario Tama / Getty via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial

    The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.

  • 3D Rendering of a Natural Killer Cell (NK Cell) destroying a cancer cell.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Artiva to quit autoimmune cell therapy work, cut staff after patient deaths

    The disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.

  • Spermatozoon is injected into an ovum with help of microneedle and holding pipette underneath a microscope
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Ferring to acquire next-gen IVF startup Gameto for up to $1.4B

    The buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro fertilization.

    Updated Oct. 28, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Lilly shuffles business structure; Novartis writes off part of Avidity deal

    Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.

  • Two boxes of "Wegovy (semaglutide injection 1mg/.5 ml)" lie on a grey granite countertop.
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Obesity drugs

    Court rejects Novo bid to block Lilly obesity drug ads

    Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the Danish company’s sales, a federal judge ruled.

  • Street signs for the intersection of Wall St. and Broad St., with the stripes of an American flag in the background.
    Image attribution tooltip
    Michael Santiago/Getty Images via Getty Images
    Image attribution tooltip
    Obesity drugs

    Corxel, an obesity drugmaker, to go public via SPAC deal

    Armed with a $300 million financing and two GLP-1 and amylin-targeting medicines, Corxel is set to become the latest weight loss-focused company to join the public markets. 

  • An illustration of immune cells attacking a tumor.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Moderna, Merck shares fall on eagerly anticipated cancer vaccine results

    A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction,” one analyst wrote.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Another autoimmune CAR-T death; Treasury zeroes in on China deals

    A patient who received Bristol Myers’ zola-cel died 44 days later. Elsewhere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.

  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    This week in charts: a big year for RNAi developers

    The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi developers, and the funding that came with it.

  • A BioNTech logo hangs on the side of an office building.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study

    The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Aspen Neuroscience and Bambusa Therapeutics could on Thursday evening price what would be the sector’s 28th and 29th IPOs, respectively, this year, according to BioPharma Dive data.

    Updated Oct. 29, 2026
  • Space stars and nebula as purple abstract background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Star adds $200M after spinout successes

    Following exits for its subsidiaries Electra Therapeutics and Vega Therapeutics, Star is now mining for a new drug prospect.

  • A street sign for Wall Street in front of the facade of the New York Stock Exchange.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Protein degrader specialist Lycia prices $318M IPO

    Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as well as the autoimmune disorder Graves’ disease.

  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip

    Roche affirms sales outlook amid doubts about its future

    Lower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top products.